Johnson & Johnson reported first-quarter earnings that beat Wall Street expectations on Tuesday and raised its full-year forecast, as strong demand for cancer drug Darzalex and psoriasis ​treatment Tremfya more than offset a steep ​falloff in sales of its ​blockbuster autoimmune drug Stelara. The drug and device maker reported first-quarter revenue of $24.1 billion, up nearly 10% from a year earlier. That exceeded analysts' estimates of $23.6 billion, according to LSEG data. Adjusted earnings